Skip to content

CalAmp CAMP Additional Paid-In Capital

Additional Paid-In Capital at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$3.25B+11.9%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$942.7M+29.5%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$727.05M+67.6%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$820.02M+5.1%
Polaryx Therapeutics, Inc.
 logo
Polaryx Therapeutics, Inc. PLYX
$104.66M
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$964.67M+41.6%

Other financials

Income statement

See full
Revenue$1.3M+50.8%
Operating income-$13.1M+0.2%
Net income-$18.3M-47.4%
EPS (diluted)-$0.32+48.4%

Balance sheet

See full
Cash & equivalents$100.8M+97.9%
Total debt$2.1M-73.2%
Total equity$30.9M-40.1%
Total assets$105.5M+68.0%

Cash flow

See full
Operating cash flow-$11.0M+23.1%
CapEx--100%
Free cash flow-$11.0M+24.6%

Valuation

See full
Market cap$226.92M+666%
Enterprise value$128.2M-3,860%
P/S57.7×+47.8×

Profitability

See full
Operating margin-1,335.2%-512pp
Net margin-2,193.7%-581pp
FCF margin-1,254%

Returns & leverage

See full
Return on equity-209.3%
Debt / equity0.1×-0.1×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by CalAmp in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: CalAmp’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CalAmp's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CalAmp's additional paid-in capital?
CalAmp (CAMP) reported additional paid-in capital of $341.38M in Q1 2026.
How has CalAmp's additional paid-in capital changed year-over-year?
CalAmp's additional paid-in capital increased by 23.8% year-over-year, from $275.76M to $341.38M.
What is the long-term trend for CalAmp's additional paid-in capital?
Over 2 years (2023 to 2025), CalAmp's additional paid-in capital has grown at a 206.3% compound annual growth rate (CAGR), from $36.23M to $339.85M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.